Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received an average rating of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $19.50.

Several brokerages recently issued reports on ZVRA. Maxim Group raised their target price on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. William Blair reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Monday, April 1st.

Zevra Therapeutics Trading Up 1.3 %

Zevra Therapeutics stock opened at $4.81 on Wednesday. Zevra Therapeutics has a one year low of $3.89 and a one year high of $7.28. The business’s fifty day moving average is $5.46 and its 200 day moving average is $5.37. The stock has a market capitalization of $208.90 million, a PE ratio of -3.73 and a beta of 1.87. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.18 and a quick ratio of 1.18.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.20). Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%. The company had revenue of $13.22 million for the quarter, compared to the consensus estimate of $13.35 million. On average, sell-side analysts predict that Zevra Therapeutics will post -1.65 EPS for the current year.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. IFG Advisors LLC increased its stake in shares of Zevra Therapeutics by 45.0% in the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after purchasing an additional 5,800 shares in the last quarter. Virtu Financial LLC bought a new position in Zevra Therapeutics in the 4th quarter worth $177,000. Tower Research Capital LLC TRC increased its stake in Zevra Therapeutics by 134.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock worth $63,000 after buying an additional 5,545 shares in the last quarter. Armistice Capital LLC bought a new stake in Zevra Therapeutics during the fourth quarter valued at about $1,755,000. Finally, Focus Financial Network Inc. ADV purchased a new position in shares of Zevra Therapeutics in the fourth quarter valued at about $141,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.